JP2023552678A - 粒子およびｍＲＮＡを含む医薬組成物ならびにそれを調製および貯蔵する方法 - Google Patents

粒子およびｍＲＮＡを含む医薬組成物ならびにそれを調製および貯蔵する方法 Download PDF

Info

Publication number
JP2023552678A
JP2023552678A JP2023528680A JP2023528680A JP2023552678A JP 2023552678 A JP2023552678 A JP 2023552678A JP 2023528680 A JP2023528680 A JP 2023528680A JP 2023528680 A JP2023528680 A JP 2023528680A JP 2023552678 A JP2023552678 A JP 2023552678A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
formulation
substantially free
lipid
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528680A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022101486A5 (https=
JP2023552678A5 (https=
Inventor
ハース，ハインリヒ
タンキ，カウシク
ボルケス，イサーク エルナン エスパルサ
ヘルナー，ゼバスティアン
シディコフ，ブラート
カップ，マルティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of JP2023552678A publication Critical patent/JP2023552678A/ja
Publication of JPWO2022101486A5 publication Critical patent/JPWO2022101486A5/ja
Publication of JP2023552678A5 publication Critical patent/JP2023552678A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023528680A 2020-11-16 2021-11-15 粒子およびｍＲＮＡを含む医薬組成物ならびにそれを調製および貯蔵する方法 Pending JP2023552678A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063114478P 2020-11-16 2020-11-16
US63/114,478 2020-11-16
EP2020082602 2020-11-18
EPPCT/EP2020/082602 2020-11-18
PCT/EP2021/081741 WO2022101486A1 (en) 2020-11-16 2021-11-15 Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same

Publications (3)

Publication Number Publication Date
JP2023552678A true JP2023552678A (ja) 2023-12-19
JPWO2022101486A5 JPWO2022101486A5 (https=) 2024-11-22
JP2023552678A5 JP2023552678A5 (https=) 2024-11-22

Family

ID=78617419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528680A Pending JP2023552678A (ja) 2020-11-16 2021-11-15 粒子およびｍＲＮＡを含む医薬組成物ならびにそれを調製および貯蔵する方法

Country Status (6)

Country Link
US (1) US20240033344A1 (https=)
EP (1) EP4243787A1 (https=)
JP (1) JP2023552678A (https=)
AU (1) AU2021377746A1 (https=)
CA (1) CA3198309A1 (https=)
WO (2) WO2022101486A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549266A (ja) * 2020-11-16 2023-11-22 ビオンテック・ソシエタス・エウロパエア Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524023B2 (en) * 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用
WO2024006863A1 (en) * 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN115869394A (zh) * 2022-07-21 2023-03-31 中国食品药品检定研究院 核酸佐剂、含有所述核酸佐剂的疫苗及应用
IL321279A (en) * 2022-12-23 2025-08-01 Lilly Co Eli Stabilization of lipid nanoparticle formulations
WO2024160826A1 (en) * 2023-01-31 2024-08-08 BioNTech SE Compositions and methods
US11833224B1 (en) * 2023-02-08 2023-12-05 Leuvian Llc Lyoprotectant compositions and uses thereof
KR20250153298A (ko) * 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024193827A1 (en) * 2023-03-23 2024-09-26 BioNTech SE Stabilized nucleic acid compositions and methods for preparing, storing and using the same
EP4442256A1 (en) * 2023-04-04 2024-10-09 Københavns Universitet Lipid nanoparticle compositions
TW202446402A (zh) * 2023-04-12 2024-12-01 美商艾拉倫製藥公司 用於寡核苷酸遞送之調配物
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
AU2023457271A1 (en) * 2023-06-28 2025-12-18 Global Life Sciences Solutions Canada Ulc Lipid nanoparticle formulations for cell therapy and related methods
CN121712495A (zh) * 2023-08-21 2026-03-20 环球生命科学解决方案加拿大有限公司 用于离子流脂质纳米颗粒的制造方法和装置
WO2025061153A1 (en) * 2023-09-22 2025-03-27 Everest Medicines (China) Co., Ltd. Rna-lipid particles comprising polysarcosine-lipid conjugate
WO2025087303A1 (en) * 2023-10-24 2025-05-01 Mote Therapeutics Inc. Lipid nanoparticle with non-covalent bifunctional binders for active targeting
WO2025133105A1 (en) * 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025176732A1 (en) 2024-02-20 2025-08-28 BioNTech SE Compositions and methods
WO2025261607A1 (en) 2024-06-21 2025-12-26 BioNTech SE Particles, compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534992A (ja) * 2013-10-22 2016-11-10 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アルギニノコハク酸合成酵素欠損症のｍＲＮＡ治療
JP2018533573A (ja) * 2015-10-28 2018-11-15 アキィタス・セラピューティクス・インコーポレイテッドＡｃｕｉｔａｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP2019525901A (ja) * 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
JP2020504764A (ja) * 2016-10-26 2020-02-13 キュアバック アーゲー 脂質ナノ粒子ｍＲＮＡワクチン
WO2020072605A1 (en) * 2018-10-02 2020-04-09 Intellia Therapeutics, Inc. Ionizable amine lipids

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
SG11201707663SA (en) * 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
US20180303925A1 (en) 2015-04-27 2018-10-25 The Trustees Of The University Of Pennsylvania Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
BR112018069417A2 (pt) 2016-04-22 2019-01-22 Biontech Rna Pharmaceuticals Gmbh método para fornecer rna fita simples e ssrna

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534992A (ja) * 2013-10-22 2016-11-10 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アルギニノコハク酸合成酵素欠損症のｍＲＮＡ治療
JP2018533573A (ja) * 2015-10-28 2018-11-15 アキィタス・セラピューティクス・インコーポレイテッドＡｃｕｉｔａｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP2019525901A (ja) * 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
JP2020504764A (ja) * 2016-10-26 2020-02-13 キュアバック アーゲー 脂質ナノ粒子ｍＲＮＡワクチン
WO2020072605A1 (en) * 2018-10-02 2020-04-09 Intellia Therapeutics, Inc. Ionizable amine lipids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549266A (ja) * 2020-11-16 2023-11-22 ビオンテック・ソシエタス・エウロパエア Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法

Also Published As

Publication number Publication date
WO2022101486A1 (en) 2022-05-19
AU2021377746A9 (en) 2024-09-26
WO2022101471A1 (en) 2022-05-19
AU2021377746A1 (en) 2023-06-08
CA3198309A1 (en) 2022-05-19
US20240033344A1 (en) 2024-02-01
EP4243787A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
JP2023552678A (ja) 粒子およびｍＲＮＡを含む医薬組成物ならびにそれを調製および貯蔵する方法
JP2023549266A (ja) Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法
JP7446527B2 (ja) コード核酸の治療可能性についての効力アッセイ
US20240408032A1 (en) Lipid-based rna formulations suitable for therapy
CN119156205A (zh) 用于施用rna的基于脂质的制剂
CN116829134A (zh) 包含rna的lnp组合物及其制备、储存和使用方法
WO2022218503A1 (en) Lnp compositions comprising rna and methods for preparing, storing and using the same
JP2025514649A (ja) 無機ポリリン酸などの多価アニオンを含む核酸組成物ならびにその製造、保存および使用のための方法
JP2024522179A (ja) 免疫エフェクタ細胞の活性化および標的化のための薬剤および方法
JP2026508330A (ja) 多重コーディング核酸のリンカー配列効力アッセイ
US20240226132A1 (en) Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
CN120712350A (zh) 用于药物用途的rna制剂
CN116669709A (zh) 包含颗粒和mRNA的药物组合物及其制备和储存的方法
HK40099059A (zh) 包含颗粒和mrna的药物组合物及其制备和储存的方法
CN118176209A (zh) 涉及用于抗原疫苗接种的非免疫原性rna和pd-1轴结合拮抗剂的治疗
HK40100852A (zh) 包含rna的lnp组合物及其制备、储存和使用方法
CN118804763A (zh) 用于施用不同剂量rna的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260216